Head-to-head evidence
Inaxaplin vs MZE829
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: APOL1 (Apolipoprotein L1) · full Chronic Kidney Disease pipeline
Inaxaplin
Developed by Vertex Pharmaceuticals
NCT06794996 · Phase 2 · completed
This is an unblinded, single-arm study with no comparison group, and no results have been posted yet.
Next expected readout: June 2028 · NCT05312879 (registry estimate)
MZE829
Developed by Maze Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inaxaplin's landscape · MZE829's landscape